Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CTSV | O60911 | 4/20 | 0.50 |
| ▸ | CTSL | P07711 | 4/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27654714 | 0.90 | CTSV (0.58) | MAPTTDP1L3MBTL1CTSVCTSL | |
| SCHEMBL13936617 | 0.86 | MEN1 (0.56) | MAPTSMN1; SMN2L3MBTL1CTSVCTSL | |
| SCHEMBL15520248 | 0.86 | CTSV (0.49) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL340310 | 0.86 | MEN1 (0.56) | MAPTSMN1; SMN2L3MBTL1CTSVCTSL | |
| SCHEMBL4222265 | 0.85 | CTSV (0.58) | MAPTTDP1L3MBTL1CTSVCTSL | |
| SCHEMBL21052613 | 0.83 | MAOB (0.67) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL4140081 | 0.83 | MAOB (0.67) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL31738283 | 0.82 | CTSV (0.58) | MAOBTDP1L3MBTL1CTSVCTSL | |
| SCHEMBL8316504 | 0.80 | CTSV (0.61) | MAPTTDP1L3MBTL1CTSVCTSL | |
| SCHEMBL31235944 | 0.79 | CTSV (0.53) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030013868-A1 | C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support | LINDEN TECHNOLOGIES, INC., A DELAWARE CORPORATION | 2003-01-16 | — | — | US | disclosed |
| US-20030009027-A1 | C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support | LINDEN TECHNOLOGIES, INC., A DELAWARE CORPORATION | 2003-01-09 | — | — | US | disclosed |
| US-6489466-B2 | PRODUCING IMMOBILIZED OLIGONUCLEOTIDES ON A SUBSTRATE BY COVALENTLY ATTACHING A FIRST NUCLEOTIDE OR OLIGONUCLEOTIDE VIA A C-5' OXYGEN OF THE NUCLEOTIDE TO THE SUBSTRATE; C-3'OXYGEN PROTECTED WITH PHOTO- OR CHEMICAL-LABILE GROUPS | LINDEN TECHNOLOGIES, INC. | 2002-12-03 | — | — | US | disclosed |
| US-20010044530-A1 | C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support | LINDEN TECHNOLOGIES, INC. | 2001-11-22 | — | — | US | disclosed |
| WO-2001055451-A1 | C-3' PROTECTED MONOMERIC NUCLEOTIDES AND SYNTHESIS OF OLIGONUCLEOTIDES ON SOLID SUPPORT | LINDEN TECHNOLOGIES, INC. (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013868-A1 | C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support | RNGTT, BCDIN3D, NT5C3B | MAOB 1445/4885MAPT 4793/4885CYP2C9 2957/4885 |
| US-20010044530-A1 | C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support | RNGTT, BCDIN3D, NT5C3B | MAOB 1445/4885MAPT 4793/4885CYP2C9 2957/4885 |
| US-20030009027-A1 | C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support | RNGTT, BCDIN3D, NT5C3B | MAOB 1445/4885MAPT 4793/4885CYP2C9 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.